|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2014
gptkb:Canada
gptkb:European_Union
gptkb:FDA
gptkb:Japan
|
|
gptkbp:can_be_combined_with
|
gptkb:ipilimumab
|
|
gptkbp:chemical_formula
|
C634 H1008 N178 O198 S4
|
|
gptkbp:clinical_trial
|
gptkb:disease
gptkb:Oncology
ongoing
|
|
gptkbp:clinical_use
|
combination therapy
monotherapy
|
|
gptkbp:contraindication
|
active autoimmune disease
history of severe hypersensitivity
organ transplant history
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:financial_stability
|
stable for 24 hours at room temperature
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nivolumab
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
pulmonary function tests
liver function tests
thyroid function tests
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:France
gptkb:Germany
gptkb:Switzerland
gptkb:United_States
gptkb:Opdivo
|
|
gptkbp:mechanism_of_action
|
immune checkpoint inhibitor
|
|
gptkbp:patient_population
|
adults
pediatric patients
|
|
gptkbp:pharmacokinetics
|
inhibits PD-1 receptor
half-life of 25 hours
|
|
gptkbp:provides_guidance_on
|
ASCO guidelines
NCCN guidelines
|
|
gptkbp:research
|
Phase III trials
Phase I trials
Phase II trials
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:side_effect
|
fatigue
hepatitis
diarrhea
rash
immune-related adverse events
thyroid disorders
pneumonitis
colitis
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:PD-1
|
|
gptkbp:used_for
|
treatment of cancer
|
|
gptkbp:weight
|
146 k Da
|
|
gptkbp:bfsParent
|
gptkb:EMD_Serono
|
|
gptkbp:bfsLayer
|
5
|